Early prediction of neoadjuvant treatment outcome in locally advanced breast cancer using parametric response mapping and radial heterogeneity from breast MRI

2019 ◽  
Vol 51 (5) ◽  
pp. 1403-1411
Author(s):  
Stylianos Drisis ◽  
Mohammed El Adoui ◽  
Patrick Flamen ◽  
Mohammed Benjelloun ◽  
Roland Dewind ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Outcome ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Breast Mri ◽  
Early Prediction ◽  
Response Mapping ◽  
Parametric Response

scholarly journals 6ER-003 Effectiveness of neoadjuvant treatment in locally advanced breast cancer

2020 ◽  
Author(s):  
B Bertran De Lis ◽  
M Mañes ◽  
I Soto ◽  
E Maroto ◽  
EP Gómez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Advanced Breast

Prolonged neoadjuvant treatment plus GM-CSF in locally advanced breast cancer: clinical and biological concepts

2004 ◽  
Vol 6 (3) ◽  
pp. 130-139
Author(s):  
Paula Raffin Pohlmann ◽  
Laura Suchil Bernal ◽  
Adolfo Fuentes Alburo ◽  
Jan Buter ◽  
Dolores Gallardo Rincón ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Advanced Breast ◽  
Gm Csf ◽  
Biological Concepts

Epirubicin and Docetaxel as Neoadjuvant Treatment of Locally Advanced Breast Cancer: A Phase II Study

2010 ◽  
Vol 96 (2) ◽  
pp. 229-233 ◽  
Author(s):  
Davide Lombardi ◽  
Simona Scalone ◽  
Diana Crivellari ◽  
Maria Donatella Magri ◽  
Nicoletta La Mura ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Advanced Breast

A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: Response and cardiotoxicity

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10515-10515 ◽  
Author(s):  
H. R. Chang ◽  
D. Slamon ◽  
R. Prati ◽  
J. Glaspy ◽  
M. D. Pegram ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Pathologic Complete Response ◽  
Neoadjuvant Treatment ◽  
Advanced Breast ◽  
Cardiac Symptoms ◽  
Her 2

10515 Background: A phase II clinical trial was conducted to study the safety and efficacy of neoadjuvant docetaxel/carboplatin (T/C) with or without trastuzumab (H) in women with stage III breast cancer. Methods: Forty-eight of 75 planned primary breast cancer patients (T3 or T4, any N, M0), age between 18 and 80 have been enrolled. Four cycles of T (75 mg/m2) + C (AUC 6) were given every 3 weeks preoperatively. Patients with HER-2 amplified tumors (FISH +) were randomized to receive either weekly concurrent H or T/C alone preoperatively and T/C plus H postoperatively. Tumors were assessed clinically at baseline and after neoadjuvant therapy. Cardiac assessment consisted of medical history, EKG and LVEF (by echocardiogram or MUGA) at baseline and at the end of neoadjuvant chemotherapy. Results: Available data from 45 of 48 enrolled patients showed 49% (22 cases) with complete clinical response, with 54.5% being HER-2 (+) (12 cases). Stable disease was seen in one patient who was HER-2 (−) (2.2%). Of 37 with complete pathology verification, 11 (29.7%) showed pathologic complete response (pCR) of the primary tumor with 5 cases being HER-2 (+). Of the 22 HER-2 (+) cases that completed neoadjuvant treatment, 11 received T/C/H and 11 received T/C. pCR was noted in 36.4% of the T/C/H group and 9% of the T/C group. LVEF data is available from 43 patients during the neoadjuvant phase, showing 18.6% (8 cases) with decrease of ≥ 10% (5 patients in the T/C arm and 3 patients in the T/C/H arm), although none had cardiac symptoms or LVEF below the normal limit. Conclusions: T/C ± H is clinically active in patients with locally advanced breast cancer including a 30% pCR rate. The cardiotoxicity rates were comparable between patients who received T/C and T/C/H. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document